Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product

Ebbers H. et al, (2025), Rheumatology and therapy

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Taylor PC. et al, (2025), Annals of the rheumatic diseases

Long-term safety and efficacy of anti–GM-CSF otilimab in patients with rheumatoid arthritis: Long-term extension of three Phase 3 randomised trials (contRAst X)

Weinblatt ME. et al, (2025), Bmj open

Association between patient-reported pain and remission or low disease activity in patients with rheumatoid arthritis: Data from RA-BE-REAL prospective observational study

Taylor PC. et al, (2024), Rheumatology and therapy

Towards better personalised care in rheumatoid arthritis

Taylor PC., (2024), Rheumatology

Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints.

Puntmann VO. et al, (2024), J cardiovasc magn reson

Does concomitant use of methotrexate with JAK inhibition confer benefit for cardiovascular outcomes? A commentary

Taylor PC. et al, (2024), Rheumatology and therapy

Inflammatory disease status and response to TNF blockade are associated with mechanisms of endotoxin tolerance.

Clanchy FI. et al, (2024), J autoimmun, 148

What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?

Taylor PC. et al, (2024), Therapeutic advances in musculoskeletal disease

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

Buch MH. et al, (2024), Rheumatology

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis

Smolen JS. et al, (2024), Rheumatology

A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor

Caporali R. et al, (2024), Advances in therapy

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial

Uhrenholt L. et al, (2024), Rheumatology international

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis

Taylor PC. et al, (2024), Rheumatology and therapy

The rheumatoid arthritis impact of disease (RAID) score in telemedicine management of rheumatoid arthritis

Taylor PC., (2024), Journal of rheumatology

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.

Worth C. et al, (2024), Lancet rheumatol

Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Participants With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Therapy: Results From the Phase 2a IRIS-RA Study

Taylor PC. et al, (2024), Rmd open

Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain

Baerwald CG. et al, (2024), Annals of the rheumatic diseases

A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

Jones C. et al, (2024), Lancet rheumatology

Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study

Caporali R. et al, (2024), Rheumatology

Load More